Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01474174 · ClinicalTrials.gov registry record
Trivalent Influenza Vaccine in Preventing Flu in Patients With Central Nervous System Tumors
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 38
- Enrollment target
NCT01474174 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 38 participants.
The verdict
NCT01474174 has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 38 participants
- Enrollment target
Study Summary
This pilot clinical trial studies trivalent influenza vaccine in preventing flu in patients with central nervous system (CNS) tumors. Flu vaccine may help the body build an effective immune response and help prevent flu in patients who are receiving chemotherapy for CNS tumors
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL trivalent influenza vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01474174
The ClinicalTrials.gov registry entry for NCT01474174 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT01474174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01474174 about?
NCT01474174 is a clinical study titled "Trivalent Influenza Vaccine in Preventing Flu in Patients With Central Nervous System Tumors". This pilot clinical trial studies trivalent influenza vaccine in preventing flu in patients with central nervous system (CNS) tumors. Flu vaccine may help the body build an effective immune response and help prevent flu in patients who are receiving chemotherapy for CNS tumors
What is the current status of trial NCT01474174?
This trial is currently completed. The enrollment target is 38 participants. The study started on 2011-09. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01474174?
The interventions under investigation include: laboratory biomarker analysis (OTHER), trivalent influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01474174?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.